KR20070005722A - 날트렉손 장기간 작용성 제형 및 이의 사용 방법 - Google Patents

날트렉손 장기간 작용성 제형 및 이의 사용 방법 Download PDF

Info

Publication number
KR20070005722A
KR20070005722A KR1020067023387A KR20067023387A KR20070005722A KR 20070005722 A KR20070005722 A KR 20070005722A KR 1020067023387 A KR1020067023387 A KR 1020067023387A KR 20067023387 A KR20067023387 A KR 20067023387A KR 20070005722 A KR20070005722 A KR 20070005722A
Authority
KR
South Korea
Prior art keywords
naltrexone
long
days
individual
acting formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067023387A
Other languages
English (en)
Korean (ko)
Inventor
엘리오트 에리히
Original Assignee
알케르메스,인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35187918&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20070005722(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알케르메스,인코포레이티드 filed Critical 알케르메스,인코포레이티드
Publication of KR20070005722A publication Critical patent/KR20070005722A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020067023387A 2004-04-22 2005-03-18 날트렉손 장기간 작용성 제형 및 이의 사용 방법 Ceased KR20070005722A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56454204P 2004-04-22 2004-04-22
US60/564,542 2004-04-22
US11/083,167 US7919499B2 (en) 2004-04-22 2005-03-17 Naltrexone long acting formulations and methods of use
US11/083,167 2005-03-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020097009360A Division KR20090050111A (ko) 2004-04-22 2005-03-18 날트렉손 장기간 작용성 제형 및 이의 사용 방법

Publications (1)

Publication Number Publication Date
KR20070005722A true KR20070005722A (ko) 2007-01-10

Family

ID=35187918

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020067023387A Ceased KR20070005722A (ko) 2004-04-22 2005-03-18 날트렉손 장기간 작용성 제형 및 이의 사용 방법
KR1020097009360A Ceased KR20090050111A (ko) 2004-04-22 2005-03-18 날트렉손 장기간 작용성 제형 및 이의 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097009360A Ceased KR20090050111A (ko) 2004-04-22 2005-03-18 날트렉손 장기간 작용성 제형 및 이의 사용 방법

Country Status (10)

Country Link
US (5) US7919499B2 (https=)
EP (2) EP2386269A3 (https=)
JP (2) JP5426094B2 (https=)
KR (2) KR20070005722A (https=)
CN (1) CN103251597A (https=)
AU (1) AU2005239989B2 (https=)
CA (1) CA2563086C (https=)
NZ (1) NZ549976A (https=)
RU (1) RU2370257C2 (https=)
WO (1) WO2005107753A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2818973B2 (ja) 1990-10-22 1998-10-30 株式会社藤井鉄工所 スキップ式水路用スクリーン除塵機
US20100196436A1 (en) * 2009-01-30 2010-08-05 Gooberman Lance L Implants containing disulfiram and an anti-inflammatory agent
US8791093B2 (en) * 2009-05-29 2014-07-29 Lance L. Gooberman Pharmaceutical delivery systems for treatment of substance abuse and other addictions
RU2471478C1 (ru) * 2011-12-08 2013-01-10 Станислав Анатольевич Кедик Фармацевтическая композиция для лечения алкоголизма, наркомании и токсикомании с улучшенным профилем высвобождения налтрексона
WO2016160715A1 (en) * 2015-03-27 2016-10-06 Markel Dan Method for treating addiction
AU2019362730B2 (en) 2018-10-15 2022-10-20 Chong Kun Dang Pharmaceutical Corp. Injectable long-acting naltrexone microparticle compositions
KR102898979B1 (ko) 2018-12-27 2025-12-10 에일러 파마슈티컬스 아이엔씨. 주사가능한 날트렉손 서방형 약학 제제
GR1009871B (el) * 2019-07-30 2020-11-12 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει μικροσφαιριδια ναλτρεξονης και μεθοδος παρασκευης αυτου
US12343340B2 (en) 2020-12-31 2025-07-01 Soin Therapeutics Llc Methods of using low dose naltrexone to treat chronic pain
US11752143B2 (en) 2020-12-31 2023-09-12 Soin Therapeutics Llc Methods of using low dose naltrexone to treat chronic pain
US11197819B1 (en) 2021-04-09 2021-12-14 Drug Delivery Company, Llc Extended release bioabsorbable subcutaneous medicinal dosage delivery implant system
AU2022202053A1 (en) 2021-09-17 2023-04-06 Biocorrx, Inc. Biodegradable implant including naltrexone
WO2023114557A2 (en) * 2021-12-17 2023-06-22 Journey Colab Corp. METHODS OF TREATING SUBSTANCE USE DISORDERS USING 5-MeO-DMT
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4719219A (en) 1982-03-30 1988-01-12 Per A. E. Carlsson Phenyl-azacycloalkanes and use thereof in treatment of central nervous system disorders
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
WO1990013361A1 (en) 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
CA2474701C (en) 1993-11-19 2009-01-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradeable microparticles containing a biologically active agent
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
JPH11505547A (ja) * 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6306425B1 (en) * 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
RO121631B1 (ro) 1999-08-27 2008-01-30 Southern Research Institute Compoziţie cu buprenorfină şi utilizarea acesteia pentru reducerea consumului de heroină şi/sau alcool
WO2001043726A1 (en) 1999-12-16 2001-06-21 Trident Technologies, Llc System and method for extended delivery of a therapeutic agent with its receptor loading dose
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
NZ540318A (en) 2002-10-31 2007-09-28 Umd Inc Therapeutic compositions for drug delivery to and through covering epithelia
CN1166360C (zh) * 2002-11-07 2004-09-15 上海医药工业研究院 一种纳曲酮长效注射微球组合物及制备方法和应用
US7658998B2 (en) 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US7279579B2 (en) 2003-06-04 2007-10-09 Alkermes, Inc. Polymorphic forms of naltrexone

Also Published As

Publication number Publication date
CN103251597A (zh) 2013-08-21
EP2386269A2 (en) 2011-11-16
JP2011225600A (ja) 2011-11-10
US20050245558A1 (en) 2005-11-03
NZ549976A (en) 2009-11-27
US20140155424A1 (en) 2014-06-05
WO2005107753A3 (en) 2005-12-29
AU2005239989B2 (en) 2008-05-29
JP5426094B2 (ja) 2014-02-26
EP1740120A4 (en) 2008-06-25
CA2563086A1 (en) 2005-11-17
RU2006137349A (ru) 2009-04-20
WO2005107753A2 (en) 2005-11-17
JP2007533738A (ja) 2007-11-22
KR20090050111A (ko) 2009-05-19
US20110212985A1 (en) 2011-09-01
EP2386269A3 (en) 2012-04-25
AU2005239989A1 (en) 2005-11-17
US7919499B2 (en) 2011-04-05
CA2563086C (en) 2018-04-17
US20210244818A1 (en) 2021-08-12
RU2370257C2 (ru) 2009-10-20
US20180064814A1 (en) 2018-03-08
EP1740120A2 (en) 2007-01-10

Similar Documents

Publication Publication Date Title
US20210244818A1 (en) Naltrexone Long Acting Formulations and Methods of Use
AU780852B2 (en) Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
US12343371B2 (en) Method for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using a sustained release depot formulation comprising glatiramer acetate
EP3506921B1 (en) Depot systems comprising glatiramer acetate
JP7262576B2 (ja) 注射可能な長時間作用型ナルトレキソン微粒子組成物
TW202308653A (zh) 以神經活性類固醇進行治療的方法
RU2471478C1 (ru) Фармацевтическая композиция для лечения алкоголизма, наркомании и токсикомании с улучшенным профилем высвобождения налтрексона
CN1946353B (zh) 纳曲酮长效制剂和使用方法
Lin Buprenorphine microspheres: Formulations, dissolution, and subcutaneous absorption

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20061108

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070928

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080417

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20090107

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20080417

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20070928

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20090406

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20090107

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20101029

Appeal identifier: 2009101003124

Request date: 20090406

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20090506

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20090506

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20090406

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080917

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20071224

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
E801 Decision on dismissal of amendment
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20090604

PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20090604

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20090506

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080917

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20071224

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090406

Effective date: 20101029

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20101029

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20090406

Decision date: 20101029

Appeal identifier: 2009101003124